UP’s Much-Awaited Pharma Park All Set To Become A Reality By 2027

Last Updated:June 30, 2025, 15:49 IST

With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore

With construction in full swing, the park is expected to show physical results within two years. (Getty)

Uttar Pradesh’s much-awaited Pharma Park is all set to become a reality by 2027 as the state government begins work on North India’s first bulk drug and formulation hub in Lalitpur.

With construction underway on over 350 acres in the first phase, the project is expected to catalyse investments worth over Rs 12,000 crore and boost UP’s bid to become a national pharmaceutical manufacturing powerhouse.

Spearheaded by the Uttar Pradesh State Industrial Development Authority (UPSIDA), the Lalitpur Bulk Drug Pharma Park is part of UP government’s move to make the state self-reliant in bulk drug and Active Pharmaceutical Ingredient (API) production, while transforming Bundelkhand into an industrial powerhouse.

Spread over 1,472 acres, the park is being developed in phases. Construction work for the first phase, covering 353 acres, is already underway. According to UPSIDA, environmental clearances have been secured, and land allotment to industries has begun.

UPSIDA regional manager Sandeep Kumar confirmed that four pharmaceutical companies have submitted applications to set up units within the park. Of these, IJ Pharma and Badariya Pharma have already been allotted plots, while Riddhi Siddhi Pharma and JBJM Pharmaceuticals are in the final stages of the allotment process. “Contracts with two companies are complete, while documentation for the remaining two is ongoing," Kumar said.

The project has already caught the attention of prominent investors. During a recent investment roadshow in Ahmedabad, several pharma companies signed key proposals. UPSIDA CEO Mayur Maheshwari stated that the authority will conduct similar outreach initiatives in Mumbai, Chandigarh, and Hyderabad to attract more pharma players.

State-of-the-Art Infrastructure

Maheshwari described the park as a “state-of-the-art plug-and-play facility" tailored to meet global standards. “All utilities—electricity, water, waste management—are being designed for 24/7 industrial support. The entire park will be based on Zero Liquid Discharge (ZLD), ensuring that no untreated wastewater leaves the premises," he said.

The park’s underground utility network will include steam and solvent recovery systems, climate-controlled warehouses, and dedicated logistics corridors. A waste management system with a 3.53 TPD capacity, 33/11 KV sub-stations, and a 75 TPH steam distribution system will be in place to ensure operational efficiency.

Safety and support infrastructure are also in focus. Plans include CCTV surveillance, boundary fencing, emergency service centers, and in-house skilling centres for local manpower training. Affordable housing for workers and executives is also under development within the premises.

Investor Incentives

UPSIDA has rolled out a special industrial land allotment scheme for the pharma park. Plots are priced at Rs 1,914 per square meter, with an additional 2 per cent discount for one-time payment. These rates, according to UPSIDA officials, are highly competitive compared to other pharma hubs in India and are expected to attract significant interest from small and mid-sized pharmaceutical players.

“Infrastructure, regulatory clearances, and affordability are all aligned to offer investors a compelling alternative to Gujarat or Hyderabad," said Maheshwari.

Major Investments Begin Flowing In

The Lalitpur Pharma Park has already begun attracting significant industrial investments. CSL Life Sciences Pvt Ltd has proposed a Rs 200 crore investment to set up two manufacturing units—an IV Bottle Plant and an Oral Solid Dosage (OSD) Plant—spread over 5 to 7 acres. These units are expected to generate employment for over 250 people and become operational within the next two years.

In addition, Mediheath Diagnostic Pvt Ltd is establishing a healthcare and diagnostic unit on a 4,200-square-meter plot, while Gaman Irradiation has announced plans to invest Rs 35 crore in a skin treatment and irradiation facility that is projected to create around 150 jobs within 24 to 36 months.

Another major entrant, Obmed Pharma, has committed Rs 200 crore for setting up a formulation unit on a five-acre plot, which is expected to employ approximately 100 workers. These early investments signal strong industry confidence in the project and are expected to accelerate momentum as the park gains visibility on the national pharmaceutical landscape.

Strong Connectivity

The Lalitpur pharma park benefits from excellent multi-modal connectivity. The site is linked via MDR 35B, with NH-44 and NH-539 nearby, and is connected by rail through Tikamgarh and Lalitpur Junction. Air connectivity is facilitated via Khajuraho Airport (125 km away) and Lucknow Airport (385 km away).

The proximity to the Jhansi node of the Uttar Pradesh Defence Corridor adds strategic value, as does its alignment with the state’s broader goal of becoming a $1 trillion economy.

According to Maheshwari, the Lalitpur pharma park is being developed in collaboration with leading national institutions like IIT, DRDO, and private consultancy firm Assystem India Limited, which has experience working on world-class pharma parks in Visakhapatnam.

“We’re not just matching global standards — we’re aiming to surpass them," he said. “Uttar Pradesh is well-positioned to fill the gap left after tax benefits in Himachal Pradesh ended. With the right policies, infrastructure, and investor confidence, we’re ready to take the lead in pharma manufacturing."

With construction in full swing, the park is expected to show physical results within two years, potentially transforming Lalitpur into India’s premier bulk drug manufacturing hub.

Location :

Lalitpur, India, India

First Published:

News india UP’s Much-Awaited Pharma Park All Set To Become A Reality By 2027